CagriSema: The GLP-1 + Amylin Combination Coming in 2027

What Is CagriSema?

CagriSema is a fixed-dose combination of two drugs in one weekly injection:

• Semaglutide (2.4mg) — the same GLP-1 agonist in Wegovy
• Cagrilintide (2.4mg) — a long-acting amylin analog

By combining two different appetite-suppressing mechanisms, CagriSema produces more weight loss than semaglutide alone.

How Amylin Differs from GLP-1

GLP-1 and amylin both reduce appetite, but through different brain pathways:

• GLP-1 works primarily in the hypothalamus, reducing hunger signals
• Amylin works in the area postrema and brainstem, promoting fullness after meals

Combining both creates a "two-punch" effect on appetite that neither achieves alone.

Clinical Results

The REDEFINE trials showed:

• CagriSema: 22.7% body weight loss at 68 weeks
• Semaglutide alone: 15.8% at same timepoint
• Cagrilintide alone: 8.6% at same timepoint

The combination is clearly more than the sum of its parts — it exceeds retatrutide's Phase 2 data (24.2%) at similar timepoints, though direct comparison is difficult.

Dosing & Titration

Expected titration (based on trials):

• Weeks 1-4: CagriSema 0.06/0.25mg
• Weeks 5-8: 0.12/0.5mg
• Weeks 9-12: 0.24/1.0mg
• Weeks 13-16: 0.6/1.7mg
• Week 17+: 2.4/2.4mg (maintenance)

Single weekly subcutaneous injection, similar to current Wegovy.

Side Effects

Similar to semaglutide but slightly higher incidence:

• Nausea: ~30% (vs 25% with semaglutide alone)
• Injection site reactions: higher than semaglutide alone
• GI effects generally manageable with titration

When Available?

• Novo Nordisk (same company as Ozempic/Wegovy) is developing it
• FDA submission expected 2026-2027
• Potential approval: 2027
• Will likely be positioned as a step-up from Wegovy for non-responders

How It Fits the Landscape

Drug	Mechanism	Weight Loss
Semaglutide	GLP-1	15-17%
Tirzepatide	GLP-1 + GIP	20-22%
CagriSema	GLP-1 + Amylin	22-23%
Retatrutide	GLP-1 + GIP + Glucagon	28-30%

CagriSema fills the gap between tirzepatide and retatrutide, with the advantage of being developed by Novo Nordisk (easier transition from Wegovy) and having a well-understood safety profile from both components.